Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Recurrence 4 Breast Neoplasms 4 Rectal Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Colorectal Neoplasms 2 Stomach Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, B-Cell 1 Lymphoma 1 Colonic Neoplasms 1 Burkitt Lymphoma 1 Brain Neoplasms 1 Alopecia 1

Interventions

Rituximab 112 Cyclophosphamide 103 fludarabine 61 Doxorubicin 33 Vincristine 31 Etoposide 31 Prednisone 30 Lenalidomide 24 ibrutinib 22 fludarabine phosphate 21 Immunotherapy, Adoptive 19 Bendamustine Hydrochloride 19 obinutuzumab 18 Cytarabine 18 pembrolizumab 16 Magnetic Resonance Spectroscopy 16 Bortezomib 14 Specimen Handling 13 Dexamethasone 13 polatuzumab vedotin 12 CT-P10 12 venetoclax 11 Gemcitabine 11 Carboplatin 11 pirtobrutinib 10 glofitamab 10 zanubrutinib 9 Nivolumab 9 Mycophenolic Acid 9 Melphalan 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, B-Cell × Immunoconjugates × Clear all

NCT06796517 2025-01-28

Immunotherapy in Lymphoma

Seoul St. Mary's Hospital

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡